California Public Employees Retirement System cut its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 7.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 108,256 shares of the biopharmaceutical company’s stock after selling 8,800 shares during the period. California Public Employees Retirement System’s holdings in Lexicon Pharmaceuticals were worth $1,299,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Tocqueville Asset Management L.P. acquired a new stake in Lexicon Pharmaceuticals during the second quarter worth about $164,000. Dynamic Technology Lab Private Ltd acquired a new stake in Lexicon Pharmaceuticals during the second quarter worth about $205,000. LPL Financial LLC grew its position in Lexicon Pharmaceuticals by 34.1% during the first quarter. LPL Financial LLC now owns 29,172 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 7,426 shares in the last quarter. Price Capital Management Inc. acquired a new stake in Lexicon Pharmaceuticals during the second quarter worth about $1,352,000. Finally, UBS Group AG grew its position in Lexicon Pharmaceuticals by 94.5% during the first quarter. UBS Group AG now owns 218,923 shares of the biopharmaceutical company’s stock worth $1,876,000 after buying an additional 106,392 shares in the last quarter.
NASDAQ LXRX opened at $8.79 on Tuesday. The company has a debt-to-equity ratio of 8.85, a quick ratio of 2.83 and a current ratio of 2.90. The company has a market cap of $898.91 million, a price-to-earnings ratio of -6.92 and a beta of 0.73. Lexicon Pharmaceuticals, Inc. has a 1-year low of $7.42 and a 1-year high of $13.97.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $12.56 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The company’s quarterly revenue was down 74.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) earnings per share. On average, sell-side analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.38 EPS for the current year.
A number of research firms recently weighed in on LXRX. BidaskClub downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 27th. Stifel Nicolaus reissued a “buy” rating and set a $23.00 target price (down from $24.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, July 31st. ValuEngine downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, July 30th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $25.25.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/06/lexicon-pharmaceuticals-inc-lxrx-stake-lowered-by-california-public-employees-retirement-system.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Google Finance Portfolio Tips and Tricks
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.